PCSK9: from biology to clinical applications.
LDL receptor
PCSK9
PCSK9 inhibitors
cardiovascular disease
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
11
09
2018
revised:
03
10
2018
accepted:
03
10
2018
pubmed:
14
12
2018
medline:
26
2
2019
entrez:
8
12
2018
Statut:
ppublish
Résumé
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). In the last 15 years, in vitro and in vivo studies have allowed our understanding of the physiological role of PCSK9. In the current report, we review the key studies that have established the mode of action of PCSK9, leading to the development of PCSK9 inhibitors for clinical use. Data from clinical trials investigating these therapies clearly and unambiguously demonstrate the safety and efficacy of these new drugs that have the power to dramatically reduce LDL-C and associated cardiovascular diseases.
Identifiants
pubmed: 30522786
pii: S0031-3025(18)30426-4
doi: 10.1016/j.pathol.2018.10.012
pii:
doi:
Substances chimiques
Cholesterol, LDL
0
LDLR protein, human
0
PCSK9 Inhibitors
0
Protease Inhibitors
0
Receptors, LDL
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-183Informations de copyright
Copyright © 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.